Biochem/physiol Actions
LLY-283 is a potent and selective SAM-competitive PRMT5 inhibitor (IC50 = 20 nM against PRMT5-catalyzed methylation of an H4R3-derived peptide substrate) with greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets. LLY-283 inhibits Smith (Sm) antigen SmBB′ methylation in MCF7 cells (IC50 = 25 nM; 3 days) and affects MDM4 splicing in A375 cells (IC50 = 40 nM; 3 days). The diastereomer LLY-284 is less potent in the biochemical assay and is an ideal control compound for cellular studies. For characterization details of LLY-283, please visit the LLY-283 probe summary on the Structural Genomics Consortium (SGC) website.
LLY-284 is the negative control for the active probe, LLY-283. LLY-284 is available from Sigma. To learn more about and purchase LLY-284, click here.
To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
Features and Benefits
LLY-283 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.
- UPC:
- 41116012
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- SML1972-5MG
- CAS:
- 2040291-27-6
